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Abstract
Background: Screening and active case finding for Chlamydia trachomatis (CT) is recommended to prevent
reproductive morbidity. However insight in community prevalence of gonococcal infections and co-infections
with Neisseria gonorrhoea (NG) is lacking.
Methods: Nested study within a large population-based Chlamydia Screening Pilot among 21.000 persons 15–29
year. All CT-positive (166) and a random sample of 605 CT-negative specimens were as well tested for
gonococcal infection.
Results: Overall Chlamydia prevalence in the Pilot was 2.0% (95% CI: 1.7–2.3), highest in very urban settings
(3.2%; 95% CI: 2.4–4.0) and dependent of several risk factors. Four gonococcal infections were found among 166
participants with CT infection (4/166 = 2.4%; 95% CI: 0.1%–4.7%). All four had several risk factors and reported
symptoms. Among 605 CT-negative persons, no infection with NG could be confirmed.
Conclusion: A low rate of co-infections and a very low community prevalence of gonococcal infections were
found in this population based screening programme among young adults in the Netherlands. Population screening
for asymptomatic gonococcal infections is not indicated in the Netherlands. Although co-infection with
gonorrhoea among CT-positives is dependent on symptoms and well-known algorithms for elevated risks, we
advise to test all CT-positives also for NG, whether symptomatic or asymptomatic.
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Chlamydial and gonococcal infections are important
causes of reproductive morbidity [1-3]. Nucleic Acid
Amplication tests (NAATs) on self-obtained specimens
(urine, vaginal swabs) make it feasible to detect these
infections in a very effective manner, inside as well as out-
side conventional clinic settings [4-6]. In fact these new
technologies prelude a potential revolution in our ability
to control Sexually Transmitted Infections (STI). The vast
majority of STI is asymptomatic or sub-clinical and these
"hidden infections" are the key to persistence and ongo-
ing transmission on a population level. Merely treatment
of symptomatic cases will not be able to influence trans-
mission dynamics significantly.
Therefore, in many countries screening or active case find-
ing for Chlamydia trachomatis (CT) is recommended.
Although information on population prevalence of CT
becomes more widespread, unfortunately little informa-
tion on population prevalence of gonococcal infections in
the general young adult population is available. As the
feasibility of combined testing increases, this lack of infor-
mation hampers insight in the question whether or not to
integrate testing for Neisseria gonorrhoeae (NG) in Chlamy-
dia screening programmes. Insight in the rate of NG (co-
)infections in asymptomatic persons could fuel cost effec-
tivity analysis and offer evidence-based information
about the need for persons found positive in Chlamydia
screening to be tested for NG co-infection as well.
Although patients at STI clinics get a full STI screen even if
asymptomatic, this is not a routine procedure in primary
care. In the Netherlands health care seeking behaviour for
STI is geared towards primary care, the General Practi-
tioner (GP) addressing the majority of the STI-related
problems[7].
We wanted to estimate community prevalence of NG
infections and the number of dual infections in CT
infected participants in a population based screening pro-
gramme in the Netherlands.
Methods
A large population based Chlamydia screening was per-
formed (2003) by inviting 21.000 persons in urban and
rural areas for home-based urine testing. Design and
results of this study has been described in detail else-
where[8]. In summary, this representative cross-sectional
study was a stratified national probability survey accord-
ing to 'area address density'. 21000 random-selected
women and men in 4 regions, aged 15–29 years, received
a home-sampling kit and a questionnaire. Urine-samples
were returned by mail, pooled by 5 and tested by
polymerase chain reaction (PCR Roche Diagnostic Corp.,
Indianapolis, IN, USA). Positive pools were individually
retested. Treatment was possible via the GP, STI- or MHS-
clinic. 82% of patients that were tested positive in our
home-based CT screening program went to the GP for
treatment.
For the current research question all Chlamydia positive
(n = 166) and a random sample of 605 Chlamydia nega-
tive urine specimens (out of a total 8217 negatives) were
as well tested for NG infection according the manufac-
turer's instructions (Roche Diagnostic Corp., Indianapo-
Table 1: Main characteristics and risk factors of the 4 dually infected CT-positive and NG-positive cases
Case 1 Case 2 Case 3 Case 4
Sex female female female female
Age 17 yr 17 yr 17 yr 18 yr
Ethnicity Dutch Surinamese Dutch Surinamese
Level of urbanisation * high urban very high urban very high urban high urban
Level of education unknown intermediate low high
Symptoms:
Intermenstrual and/or 
postcoital bleeding
+ - + -
Painfull/frequent 
mixturation
+ + + +
Lower abdominal pain - + + +
Lifetime partners 2–5 6–10 6–10 6–10
Partners previous 6 
months
1 1 2–5 2–5
New partner previous 2 
months
- - + +
Condom use last sexual 
contact
- - - -
History of previous STI + - + -
* According to Area Address Density: very high urban (> 2500 addresses/km2); high urban (1500–2500 addresses/km2); moderate urban (1000–
1500 addresses/km2);) low urban (500–1000 addresses/km2); and rural (<500 addresses/km2) http://www.cbs.nl.Page 2 of 5
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performed by detecting the cppB gene and the multicopy
opa genes with a real-time PCR method using the Rotor-
gene instrument[9,10].
Results
In the initial Chlamydia Screening Study 10.610 persons
responded: 11% sent in a refusal card and 41% (n = 8383)
participated by sending in urine and questionnaire. Non-
response analysis showed a balance of high and low risk
categories among participants. Details have been reported
elsewhere[8,11]. Overall Chlamydia prevalence was 2.0%
(95% CI: 1.7–2.3); 2.5% (2.0–3.0%) in women and 1.5%
(1.1–1.9) in men. Chlamydia prevalence was significantly
higher in very high urbanised areas 3.2% (95% CI: 2.4–
4.0) compared to rural areas 0.6% (0.1–1.1). Infection
was also associated with self-reported ethnicity (especially
Surinamese/Antillean 8.2% [95% CI: 3.9–12.5]), number
of sex partners and symptoms.
Among 166 samples of persons who tested positive for
Chlamydia trachomatis infection, 4 gonococcal infections
were diagnosed (4/166 = 2.4%. 95% CI: 0.1%–4.7%). Ini-
tially 9/166 were reactive, but only 4 out of 9 were positive
in confirmatory PCR NG testing. All 4 persons co-infected
with NG were either 17 or 18 year, 3 reported 6–10 life-
time partners (and 2 had 2–5 partners in the past 6
month). All 4 reported symptoms (lower abdominal pain,
intermenstrual bleeding, dysuria) and no condom-use
during last sex contact. Two reported a Surinamese-Antil-
lean background. Main characteristics and riskfactors of
the 4 dually infected persons are listed in table 1. Among
605 Chlamydia-negative persons, no gonococcal infec-
tions were diagnosed. Initially 16/605 were reactive for
NG, but none could be confirmed with the additional
confirmatory test.
Conclusion
In this large national representative population based
Chlamydia Screening in the Netherlands among 21.000
persons we have reported an overall CT prevalence of 2.0
%. In order to gain insight in NG dual infections we
retested all positive CT specimens and found a low rate of
NG co-infections (2.4%; 4/166) among CT positives. We
found no NG infections at all among a random subset of
605 CT negative samples, suggesting a very low commu-
nity prevalence of gonococcal infections in the young
adult population. Given this very low NG prevalence, gen-
eral population screening for asymptomatic NG infec-
tions is not indicated in the Netherlands and targeted
screening is a better and more cost-effective option. For
instance, at the Amsterdam STI clinic 10% of the (hetero-
sexual) visitors had CT infection and 2.5% GC infection;
with much higher rates in MSM (CT:13% NG:14%) and in
Surinamese-Antillean population (CT: 16% NG:
7.6%)[12]. The inequalities in rates of CT and NG in black
ethnic groups are well known[13,14]. We also found con-
siderable higher CT prevalence (8.2%) among Surinamese
Antillean persons in our initial CT screening, and ethnic-
ity remained an independent variable in our prediction
rule for selective CT-screening[11]. Also 2 out of the 4 pos-
itive NG participants had a Surinamese/Antillean back-
ground, which is remarkable because only 1.6% of all
participants in our screening belonged to this ethnicity.
NG infections are even more than CT infections concen-
trated within particular risk groups, within specific risk
networks and entangled in specific risk environments[15].
The number of reported dual infections in the literature
varies considerably, from less than 1% up to more than
40% [16-18]. Most studies have been performed in clini-
cal settings among selected patient groups and often relate
to the proportion concurrent CT infections in NG infected
persons. This relation has been reported consistently high
and justifies the policy of giving antibiotic treatment for
Chlamydia at the time of Gonorrhoea diagnoses, when
CT results are not available. However, the opposite -con-
current infection with NG if CT is diagnosed – is less often
the case, and even less in CT cases found in home- or com-
munity-based screening programmes. In a Chlamydia
screening programme in the UK, prevalence of gonor-
rhoea among CT-positives was 4.6% for women and 6.3%
for men in STI clinics but only 0.2% for women and 1.2%
for men in the CT-positives found via community screen-
ing[19]. In the US, a nationally representative prevalence
study, found a CT prevalence of 4.2% and a low infection
rate for NG (0.43%) and prevalence of co-infection was
only 0.3%[20]. Substantial racial/ethnic disparities in
prevalence of both infections were reported. Some
regional home surveys in the US reported substantially
higher NG prevalence (5.3% from the Baltimore's house-
hold survey, and 3.9% in San Francisco)[5].
We could not confirm the majority of our initially positive
NG results as true positives. Certain strains of Neisse-
riaceae, considered as commensal organisms and Lactobac-
cillus species are known to produce false-positive results.
This underlines once more the necessity of confirmatory
testing in a screening programme, with a test that is more
specific and at least as sensitive[9,10].
The few persons testing positive for NG in our study were
all young women (17, 18 year) with a high risk profile (>
6 lifetime partners, no condom use during last sex and
two had Surinamese/Antillean ethnicity). All reported in
the questionnaire subjective complaints. This means that
these patients, who came to the doctor for their treatment
for the CT infection detected by home-based screening,
are in fact entitled for a STI screen according to current
guidelines and algorithms (symptomatic patients with aPage 3 of 5
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suggests that even in participants who turn out CT-posi-
tive in a population screening programme in a low preva-
lence area, a routine NG screen would not be required if
proper risk-assesment is made by the physician to tailor
further need for a full STI screen. However, risk assess-
ment in primary care is not always optimal and discussing
sexual health in GP is not always easy, not for the doctor,
nor for the patient[21]. We would argue therefore that
pursuing in primary care the old paradigm: "always look
for another STI if one STD is found" would be most prac-
tical. However, cost-effectiveness of such a strategy would
depend very much on regional STI epidemiology.
As integrated combo-tests for diagnosing CT, NG, but also
for Trichomonas, Mycoplasma, and even HIV might
become within reach in the near future, and incremental
costs for testing for these additional STI will become more
favourable from a cost-effective point of view, special con-
sideration should be paid to the potential negative side-
effects and the enhanced likelihood of false-positive
results if screening takes place in very low prevalence set-
tings[22].
Conclusion
Based on our results, population screening for gonococcal
infections is not indicated in the Netherlands. NG co-
infection in persons who tested Chlamydia positive in
population screening programmes in young adults is
dependent on symptoms and well known algorithms for
elevated risks. Routine screening for dual infections in CT-
positive participants is still recommended, whether symp-
tomatic or asymptomatic. Compared to other countries,
the Netherlands still has a low burden of STI.
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